Immatics (IMTX) Non-Current Deffered Revenue (2019 - 2025)
Immatics (IMTX) reported Non-Current Deffered Revenue of $21.6 million for Q4 2025, down 40.88% on a YoY basis from $36.5 million in Q4 2024, and down 40.88% sequentially from $36.5 million in Q4 2024.
Immatics (IMTX) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Non-Current Deffered Revenue data on file, last reported at $21.6 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 40.88% year-over-year to $21.6 million; the trailing twelve-month figure through Dec 2025 stood at $21.6 million (down 40.88% YoY), and the FY2025 full-year result was $20.9 million, down 43.34% from the prior year.
- Non-Current Deffered Revenue declined to $21.6 million in Q4 2025, from $36.5 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $124.3 million in Q4 2023 to a low of $21.6 million in Q4 2025.
- A 5-year average of $63.0 million and a median of $55.2 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue surged 60.82% in 2023 and slumped 70.63% in 2024, its largest moves.
- Tracing IMTX's Non-Current Deffered Revenue over 5 years: stood at $55.2 million in 2021, then soared by 40.1% to $77.3 million in 2022, then surged by 60.82% to $124.3 million in 2023, then slumped by 70.63% to $36.5 million in 2024, then sank by 40.88% to $21.6 million in 2025.
- Business Quant data shows IMTX's Non-Current Deffered Revenue at $21.6 million in Q4 2025, $36.5 million in Q4 2024, and $124.3 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immatics | 1.14 Bn | 1.14 Bn | - | 21.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.58 Mn |
| Dec 31, 2024 | 36.50 Mn |
| Dec 31, 2023 | 124.30 Mn |
| Dec 31, 2022 | 77.29 Mn |
| Dec 31, 2021 | 55.17 Mn |
| Dec 31, 2020 | 101.91 Mn |
| Dec 31, 2019 | 94.61 Mn |